Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

UHS — Universal Health Services

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 11.19%
Profit Margins 8.56%
Return on Equity 21.37%
Return on Assets 8.35%
Free Float 0.05B
Dividend Yield 0.55%
Short Int % Utilisation 7.03%

2.2 Growth

Metric Value
Revenue Growth 9.6%
Free Cash Flow 0.65B
EBITDA 5.21 (Ratio)
Enterprise Value 13.91B
EV/Revenue 0.78
EV/EBITDA 5.21

Revenue growth of 9.6% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 0.74%
Risk / Std Dev (Ann.)* 32.08%
1-Year Price Return* -4.33%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $170.02
52-Week Range $140.08 – $246.33
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue $17.36B $15.83B
Net income Reported net income $1.49B $1.14B
Total assets Year-end reported balance $15.53B $14.47B
Shareholders’ equity Year-end reported balance $7.28B $6.67B
Net margin Net income ÷ revenue 8.57% 7.22%
Asset turnover Revenue ÷ total assets 1.1183x 1.0939x
Equity multiplier Total assets ÷ shareholders’ equity 2.1341x 2.1706x
ROE Net margin × asset turnover × equity multiplier 20.46% 17.13%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $17.36B
Prior annual revenue $15.83B
EBIT $2.12B
Tax rate 23.40%
NOPAT = EBIT × (1 − tax rate) $1.63B
Forecast start-growth basis 9.71%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $1.63B
Add: depreciation & amortisation $618.74M
Less: capital expenditure -$1.04B
Less/(add): working-capital cash-flow movement -$16.42M
Current unlevered FCFF $1.19B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 9.71% $1.79B $678.82M -$1.14B -$18.01M $1.31B $1.26B
2 7.91% $1.93B $732.50M -$1.11B -$19.44M $1.53B $1.37B
3 6.11% $2.04B $777.22M -$1.04B -$20.62M $1.76B $1.46B
4 4.30% $2.13B $810.66M -$948.59M -$21.51M $1.97B $1.52B
5 2.50% $2.19B $830.93M -$830.93M -$22.05M $2.16B $1.54B

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 1.06
Cost of equity 10.56%
Pre-tax cost of debt 3.01%
WACC 7.81%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $41.79B
Implied terminal EV / EBITDA 11.35x
Terminal value as % of enterprise value 80.07%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $7.14B
Present value of terminal value $28.70B
Indicated enterprise value $35.85B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $35.85B
Less: gross interest-bearing debt $5.17B
Add: cash and equivalents $137.80M
Add: affiliate investments $0.00
Less: minority interests $133.62M
Indicated common equity value $30.68B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 64,462,000.00
Share-count basis reported diluted weighted-average shares
Current market price $175.16
DCF indicative value per share $475.99
Indicative value vs. market price 171.74%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 4/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:52:36.731663 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -29.86% -16.43%
Adjusted R² 0.03 0.09
Annualised residual volatility 30.55% 29.47%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.49 (2.73) 0.84 (4.21)
Size (SMB) -0.22 (-0.90) -0.04 (-0.15)
Value (HML) 0.55 (2.64) 0.40 (1.61)
Profitability (RMW) NM 0.82 (3.90)
Investment (CMA) NM -0.07 (-0.18)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequityuhshealth-carehealth-care-facilitiesnasdaq